News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Janssen Biotech has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell...
The company makes available its Process Manager software, which digitizes the end-to-end risk-based cleaning validation lifecycle.
Cytiva and the life sciences business of Pall Corporation are now united as one business under the Cytiva brand, with the completion of the integration announced this morning. Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, tells...
Originally announced in 2021, the company expects the US facility for plasma treatments to be ready by the end of 2024.
The company secures a positive opinion from the EMA, making it likely that its RSV vaccine will gain approval in Europe by July 2023.